NRAS and cancer: Even though a patient may not have BRAF mutation, inhibition of BRAF may still be effective in initially controlling the cancer if the BRAF pathway was activated via alternative pathways, such as BRAF amplification, NRAS mutation, etc. These wild‐type samples contain RAS mutations, a possible explanation for the high BRAF scores and increased sensitivity to the BRAF inhibitors, since the RAS isoforms functions to signal activation of BRAF.32